1. Home
  2. ABOS

as of 12-11-2025 4:00pm EST

$1.96
+$0.06
+3.16%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Chart Type:
Time Range:
Founded: 1996 Country:
United States
United States
Employees: N/A City: NEWTON
Market Cap: 113.9M IPO Year: 2021
Target Price: $7.67 AVG Volume (30 days): 139.2K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.21 EPS Growth: N/A
52 Week Low/High: $0.86 - $2.46 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered ABOS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 68.24%
68.24%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: